★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Medtronic plc (MDT) Moat Analysis
Medtronic plc
MDT · New York Stock Exchange
Partial score covering 76% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Medtronic is a global medical-device company whose strongest advantages are procedure-specific training and installed platforms in cardiovascular and neuroscience, remote-monitoring workflow integration, and recurring diabetes consumables. Regulatory compliance, broad product portfolios and GPO contracting are not treated as stand-alone moats because they are common among large device peers or can reflect buyer power. MiniMed completed its IPO in March 2026; Medtronic retained 90.03%, still consolidates the business and plans further separation steps within fiscal 2027. Medical Surgical remains the least differentiated portfolio. Key risks are clinical displacement, recalls and quality failures, hospital purchasing power, interoperability and MiniMed separation costs.
Primary segment
Cardiovascular Portfolio
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
4 segments · 6 tags
Updated 2026-07-12
Segments
Cardiovascular Portfolio
Cardiovascular medical devices (cardiac rhythm management, electrophysiology/ablation, structural heart, coronary & peripheral vascular)
Revenue
38.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Neuroscience Portfolio
Neurosurgical, spinal, neurovascular, and neuromodulation medical devices (including navigation/robotics and implant therapies)
Revenue
28.4%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Medical Surgical Portfolio
Surgical & endoscopy devices/consumables and acute care monitoring/airway management
Revenue
24.4%
Structure
Competitive
Pricing
weak
Share
—
Peers
MiniMed / Diabetes (consolidated all other)
Intensive insulin management technology (insulin pumps, CGM, smart insulin delivery and associated software)
Revenue
8.6%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Moat Claims
Cardiovascular Portfolio
Cardiovascular medical devices (cardiac rhythm management, electrophysiology/ablation, structural heart, coronary & peripheral vascular)
Revenue share based on FY2026 segment net sales in the June 3, 2026 earnings release: Cardiovascular USD 13,976m out of the four displayed segment rows totaling USD 36,190m. Operating-profit share remains based on FY2025 Form 10-K Note 19 because FY2026 segment operating profit was not disclosed in the FY2026 earnings release.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Remote monitoring and device data platforms embed Medtronic in clinic workflows, reducing willingness to switch implanted-device vendors for managed patients.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Vendor-neutral monitoring platforms and interoperability requirements
- Cybersecurity incidents reducing adoption of connected services
Leading indicators
- Connected-device attachment rates and active monitoring enrollments
- Software/service renewal rates and NPS from clinics
Counterarguments
- Hospitals may prioritize clinical outcomes/price over software workflow
- Competitors offer comparable remote monitoring ecosystems
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Specialty-aligned sales/clinical teams and physician relationships support adoption in procedure-based care; training and protocol familiarity raise switching friction.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Hospital consolidation and centralized purchasing reducing physician influence
- Tender-based procurement emphasizing price
Leading indicators
- Share trends in core franchises (CRM, TAVR, ablation)
- Average selling price (ASP) trends and contract win rates
Counterarguments
- Large customers can standardize vendors, forcing switches despite relationships
- Major safety advisories or trial results can shift share quickly
Neuroscience Portfolio
Neurosurgical, spinal, neurovascular, and neuromodulation medical devices (including navigation/robotics and implant therapies)
Revenue share based on FY2026 segment net sales in the June 3, 2026 earnings release: Neuroscience USD 10,287m out of the four displayed segment rows totaling USD 36,190m. Operating-profit share remains based on FY2025 Form 10-K Note 19 because FY2026 segment operating profit was not disclosed in the FY2026 earnings release.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Surgeon training, installed capital (navigation/robotics), and procedure workflows increase friction to switch implant and capital platforms within spine/cranial procedures.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Hospital capital spending slowdowns delaying platform refresh cycles
- Competing robotics/navigation ecosystems displacing incumbents
Leading indicators
- Capital system placements and utilization / pull-through of implants
- Surgeon adoption metrics for new systems and software modules
Counterarguments
- Switching can happen when hospitals standardize on a single robotics platform
- Best-in-class point solutions may outperform integrated suites
Ecosystem Complements
Network
Ecosystem Complements
Strength
Durability
Confidence
Evidence
Integrated 'ecosystem' approach (imaging + navigation/robotics + planning software + implants) enables cross-sell and workflow integration in spine/cranial care.
Ecosystem Complements moat: definition, examples, and stocks
Erosion risks
- Open interoperability reducing value of a single-vendor ecosystem
- Competitors bundling comparable ecosystems at lower total cost
Leading indicators
- Attachment of implants to capital placements (pull-through rate)
- Software utilization and renewal rates for planning/analytics
Counterarguments
- Hospitals may mix vendors for capital and implants to optimize pricing
- Surgeon preference can override ecosystem bundling
Medical Surgical Portfolio
Surgical & endoscopy devices/consumables and acute care monitoring/airway management
Revenue share based on FY2026 segment net sales in the June 3, 2026 earnings release: Medical Surgical USD 8,815m out of the four displayed segment rows totaling USD 36,190m. Operating-profit share remains based on FY2025 Form 10-K Note 19 because FY2026 segment operating profit was not disclosed in the FY2026 earnings release.
Insufficient segment-specific evidence to assign a moat claim.
MiniMed / Diabetes (consolidated all other)
Intensive insulin management technology (insulin pumps, CGM, smart insulin delivery and associated software)
Revenue share uses FY2026 Diabetes revenue of USD 3,112m out of the four displayed portfolio rows totaling USD 36,190m. MiniMed completed its IPO on March 9, 2026 and is no longer a Medtronic reportable segment, but Medtronic retained 90.03% and therefore still consolidates its results. Medtronic plans further separation steps within fiscal 2027.
Ecosystem Complements
Network
Ecosystem Complements
Strength
Durability
Confidence
Evidence
Integrated system across automated insulin delivery (pump), CGM, dosing app, and data integration increases platform value and can reduce switching for intensively managed patients.
Ecosystem Complements moat: definition, examples, and stocks
Erosion risks
- Interoperable pump/CGM standards enabling mix-and-match ecosystems
- Payer formulary decisions favoring competitors
- Further separation from Medtronic creates transition costs and potential dis-synergies
Leading indicators
- CGM attachment rates and retention in MiniMed installed base
- Regulatory clearances for interoperable pump/algorithm integrations
- Medtronic disposal or distribution of its remaining MiniMed stake
Counterarguments
- Users may prefer best-in-class CGM/pump combinations across vendors
- Competitors with stronger consumer brand or sensor accuracy can dominate
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Pump installed base drives recurring demand for consumables (infusion sets/reservoirs) and sensor supplies, supporting recurring revenue and customer stickiness.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Competitive switching at hardware upgrade cycles
- Supply shortages or quality issues in consumables
- Alternative therapies (e.g., GLP-1 drugs) reducing pump adoption
Leading indicators
- Upgrade/renewal rates for pump users
- Consumables revenue per active user
- Quality metrics and complaint rates
Counterarguments
- Consumables are not fully captive if users switch ecosystems
- Price competition and reimbursement caps can compress margins
Evidence
Remote monitoring services and patient-centered software
Implanted-device follow-up relies on monitoring workflows; vendor change can create operational friction for clinics managing installed bases.
Paraphrase: Sales teams are organized around physician specialties to foster relationships, support customers, and cross-sell complementary products.
Procedure support and specialty relationships are a key commercial advantage in cardiovascular implants and interventional therapies.
imaging, navigation, power instruments, and robotic guidance systems
Capital platforms plus clinical support can create multi-year stickiness at the account and surgeon level.
Paraphrase: Portfolio includes imaging, navigation, power instruments, robotic guidance, and AI-driven planning used in spine and cranial procedures.
Complements can reinforce adoption because value increases when multiple components are deployed together.
Paraphrase: Diabetes segment includes pumps with smartphone connectivity, CGM platforms, and a smart pen app that integrates insulin dosing with CGM data.
Supports integrated ecosystem claim (device + sensor + app) that can create multi-product lock-in.
Showing 5 of 7 sources.
Risks & Indicators
Erosion risks
- Vendor-neutral monitoring platforms and interoperability requirements
- Cybersecurity incidents reducing adoption of connected services
- Hospital consolidation and centralized purchasing reducing physician influence
- Tender-based procurement emphasizing price
- Hospital capital spending slowdowns delaying platform refresh cycles
- Competing robotics/navigation ecosystems displacing incumbents
Leading indicators
- Connected-device attachment rates and active monitoring enrollments
- Software/service renewal rates and NPS from clinics
- Share trends in core franchises (CRM, TAVR, ablation)
- Average selling price (ASP) trends and contract win rates
- Capital system placements and utilization / pull-through of implants
- Surgeon adoption metrics for new systems and software modules
Research MDT elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.